InvestSMART

PYC Therapeutics Limited (ASX:PYC)

ALERT: Price-sensitive ASX Announcement for PYC
Current share price for PYC : $1.540 0.23 (17.56%)+
Announcement
Release
28 Apr 2026 9:12AM
Price at Release
$1.310
Full Release
download
Summary
PYC Therapeutics Limited is advancing its clinical trials for Polycystic Kidney Disease and Autosomal Dominant Optic Atrophy, with significant progress noted in enrolment and dosing. The company's financial report for the quarter ending March 31, 2026, reveals strong cash reserves and a recent R&D rebate. Despite substantial R&D expenses, PYC's financing activities have bolstered its financial position, ensuring continued advancement of its drug development programs for genetic diseases like Retinitis Pigmentosa type 11 and Phelan-McDermid Syndrome.
Key Points
  • PYC is progressing through Phase 1a/1b clinical studies for Polycystic Kidney Disease (PKD) and Autosomal Dominant Optic Atrophy (ADOA).
  • The company reported enrolment and dosing advancements in its clinical trials, with plans for further studies in Q2 2026.
  • PYC's financial position as of March 31, 2026, includes $667 million in cash and a $23 million R&D rebate.
  • The company reported $16,666,000 in research and development expenses for the quarter.
  • PYC is working on drug candidates for Retinitis Pigmentosa type 11 (RP11) and Phelan-McDermid Syndrome (PMS).
  • The Appendix 4C cash flow report outlines a net cash use of $16,262,000 in operating activities for the quarter.
  • PYC's financing activities brought in a net $563 million due to equity securities issuance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.